Selective Antibodies Limited

POWER SEARCH PRICING

SOLUTIONS

selective antibodies limited Company Information

Company Number

02575564

Next Accounts

Aug 2025

Directors

Colin Self

Declan Cunningham

Shareholders

colin henry self

declan thomas cunningham

View All

Group Structure

View All

Industry

Research and experimental development on biotechnology

Registered Address

2 gosforth park avenue, newcastle upon tyne, NE12 8EG

Website

www.selectiveantibodies.com

selective antibodies limited Estimated Valuation

£28.2k

Pomanda estimates the enterprise value of SELECTIVE ANTIBODIES LIMITED at £28.2k based on a Turnover of £26.3k and 1.07x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Selective Antibodies Limited is a live company located in newcastle upon tyne, NE12 8EG with a Companies House number of 02575564. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in January 1991, it's largest shareholder is colin henry self with a 54.8% stake. Selective Antibodies Limited is a mature, micro sized company, Pomanda has estimated its turnover at £26.3k with declining growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Selective Antibodies Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 8 areas for improvement. Company Health Check FAQs

Health Rating1.5out of 5

1 Strong

1 Regular

8 Weak

Size

annual sales of £26.3k, make it smaller than the average company (£3.4m)

Growth

3 year (CAGR) sales growth of -26%, show it is growing at a slower rate (12.5%)

EXPORT

Selective Antibodies Limited's latest turnover from November 2023 is estimated at £26.3 thousand and the company has net assets of £14.9 thousand. According to their latest financial statements, we estimate that Selective Antibodies Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Nov 2023	Nov 2022	Nov 2021	Nov 2020	Nov 2019	Nov 2018	Nov 2017	Nov 2016	Nov 2015	Nov 2014	Nov 2013	Nov 2012	Nov 2011	Nov 2010	Nov 2009
Turnover	26,262	57,707	65,896	63,924	69,664	89,853	131,997	72,389	113,374	179,497	140,698	173,981	253,850	291,084	0
Other Income Or Grants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cost Of Sales	19,425	39,960	49,379	41,661	46,956	60,997	90,059	49,670	77,352	125,217	104,524	132,531	192,337	204,192	0
Gross Profit	6,837	17,747	16,517	22,263	22,708	28,856	41,938	22,719	36,022	54,280	36,174	41,450	61,513	86,893	0
Admin Expenses	12,440	23,340	18,418	1,949	34,613	63,526	-26,667	47,576	104,757	58,705	-88,743	168,916	-24,810	177,807	-214,190
Operating Profit	-5,603	-5,593	-1,901	20,314	-11,905	-34,670	68,605	-24,857	-68,735	-4,425	124,917	-127,466	86,323	-90,914	214,190
Interest Payable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest Receivable	0	0	0	0	0	0	0	26	294	482	252	99	1,630	2,037	494
Pre-Tax Profit	-5,603	-5,593	-1,901	20,314	-11,905	-34,670	68,605	-24,831	-68,441	-3,943	125,169	-127,367	87,953	-88,877	214,683
Tax	0	0	0	-3,860	0	0	-13,035	0	0	0	-28,789	0	-22,868	0	-60,111
Profit After Tax	-5,603	-5,593	-1,901	16,454	-11,905	-34,670	55,570	-24,831	-68,441	-3,943	96,380	-127,367	65,085	-88,877	154,572
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Retained Profit	-5,603	-5,593	-1,901	16,454	-11,905	-34,670	55,570	-24,831	-68,441	-3,943	96,380	-127,367	65,085	-88,877	154,572
Employee Costs	75,874	72,980	70,920	67,945	130,686	129,019	55,189	57,438	54,381	109,465	51,256	104,187	103,128	103,617	0
Number Of Employees	1	1	1	1	2	2	1	1	1	2	1	2	2	2	0
EBITDA*	-5,603	-5,593	-1,901	20,314	-11,905	-34,670	68,605	-24,857	-67,398	-2,390	131,373	-97,014	101,584	-89,258	239,671

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Nov 2023	Nov 2022	Nov 2021	Nov 2020	Nov 2019	Nov 2018	Nov 2017	Nov 2016	Nov 2015	Nov 2014	Nov 2013	Nov 2012	Nov 2011	Nov 2010	Nov 2009
Tangible Assets	2,801	3,217	485	2,587	3,883	1,040	2,265	667	180	1,517	3,591	4,608	33,446	28,459	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments & Other	0	0	0	0	0	0	0	0	100	100	100	100	100	100	100
Debtors (Due After 1 year)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Fixed Assets	2,801	3,217	485	2,587	3,883	1,040	2,265	667	280	1,617	3,691	4,708	33,546	28,559	100
Stock & work in progress	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Trade Debtors	12,144	23,774	27,781	28,856	16,491	25,074	58,595	28,954	41,808	52,554	41,192	58,145	42,653	55,897	42,187
Group Debtors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Misc Debtors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	0	0	0	0	0	0	0	0	20,735	96,889	96,018	4,811	34,626	617,246	197,485
misc current assets	0	0	0	0	0	0	0	0	0	93,001	94,043	60,208	595,746	0	0
total current assets	12,144	23,774	27,781	28,856	16,491	25,074	58,595	28,954	62,543	242,444	231,253	123,164	673,025	673,143	239,672
total assets	14,945	26,991	28,266	31,443	20,374	26,114	60,860	29,621	62,823	244,061	234,944	127,872	706,571	701,702	239,772
Bank overdraft	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bank loan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Trade Creditors	15	6,458	2,140	3,416	8,801	2,636	2,712	27,043	35,310	148,107	135,047	124,355	575,687	635,903	85,096
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other short term finances	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
hp & lease commitments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other current liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
total current liabilities	15	6,458	2,140	3,416	8,801	2,636	2,712	27,043	35,310	148,107	135,047	124,355	575,687	635,903	85,096
loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
hp & lease commitments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accruals and Deferred Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
provisions	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
total long term liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
total liabilities	15	6,458	2,140	3,416	8,801	2,636	2,712	27,043	35,310	148,107	135,047	124,355	575,687	635,903	85,096
net assets	14,930	20,533	26,126	28,027	11,573	23,478	58,148	2,578	27,513	95,954	99,897	3,517	130,884	65,799	154,676
total shareholders funds	14,930	20,533	26,126	28,027	11,573	23,478	58,148	2,578	27,513	95,954	99,897	3,517	130,884	65,799	154,676

	Nov 2023	Nov 2022	Nov 2021	Nov 2020	Nov 2019	Nov 2018	Nov 2017	Nov 2016	Nov 2015	Nov 2014	Nov 2013	Nov 2012	Nov 2011	Nov 2010	Nov 2009
Operating Activities
Operating Profit	-5,603	-5,593	-1,901	20,314	-11,905	-34,670	68,605	-24,857	-68,735	-4,425	124,917	-127,466	86,323	-90,914	214,190
Depreciation	0	0	0	0	0	0	0	0	1,337	2,035	6,456	30,452	15,261	1,656	25,481
Amortisation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tax	0	0	0	-3,860	0	0	-13,035	0	0	0	-28,789	0	-22,868	0	-60,111
Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Debtors	-11,630	-4,007	-1,075	12,365	-8,583	-33,521	29,641	-12,854	-10,746	11,362	-16,953	15,492	-13,244	13,710	42,187
Creditors	-6,443	4,318	-1,276	-5,385	6,165	-76	-24,331	-8,267	-112,797	13,060	10,692	-451,332	-60,216	550,807	85,096
Accruals and Deferred Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Taxes & Provisions	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash flow from operations	-416	2,732	-2,102	-1,296	2,843	-1,225	1,598	-20,270	-169,449	-692	130,229	-563,838	31,744	447,839	222,469
Investing Activities
capital expenditure	416	-2,732	2,102	1,296	-2,843	1,225	-1,598	-487	0	39	-5,439	-1,614	-20,248	-30,115	-25,481
Change in Investments	0	0	0	0	0	0	0	-100	0	0	0	0	0	0	100
cash flow from investments	416	-2,732	2,102	1,296	-2,843	1,225	-1,598	-387	0	39	-5,439	-1,614	-20,248	-30,115	-25,581
Financing Activities
Bank loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Short Term Loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long term loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hire Purchase and Lease Commitments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other long term liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
share issue	0	0	0	0	0	0	0	-104	0	0	0	0	0	0	104
interest	0	0	0	0	0	0	0	26	294	482	252	99	1,630	2,037	494
cash flow from financing	0	0	0	0	0	0	0	-78	294	482	252	99	1,630	2,037	598
cash and cash equivalents
cash	0	0	0	0	0	0	0	-20,735	-76,154	871	91,207	-29,815	-582,620	419,761	197,485
overdraft	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
change in cash	0	0	0	0	0	0	0	-20,735	-76,154	871	91,207	-29,815	-582,620	419,761	197,485

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for selective antibodies limited. Get real-time insights into selective antibodies limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for selective antibodies limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in NE12 area or any other competitors across 12 key performance metrics.

SELECTIVE ANTIBODIES LIMITED group structure

Selective Antibodies Limited has 1 subsidiary company.

Ultimate parent company

SELECTIVE ANTIBODIES LIMITED

02575564

1 subsidiary

AVEMONT (FOOD & DRINK) LIMITED

04298146

SELECTIVE ANTIBODIES LIMITED Shareholders

colin henry self	54.81%
declan thomas cunningham	7.69%
william gwyn cole	7.45%
david jonathan self	6.01%
alexander colin self	6.01%
ingeborg renata self	6.01%
karen jean cole	6.01%
peter james self	6.01%

Selective Antibodies Limited currently has 2 directors. The longest serving directors include Professor Colin Self (Mar 1991) and Mr Declan Cunningham (Apr 2005).

officer	country	age	start	end	role
Professor Colin Self	England	81 years	Mar 1991	-	Director
Mr Declan Cunningham		70 years	Apr 2005	-	Director

P&L

November 2023

turnover

26.3k

-54%

operating profit

-5.6k

gross margin

26.1%

-15.35%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

November 2023

net assets

14.9k

-0.27%

total assets

14.9k

-0.45%

cash

net assets

Total assets minus all liabilities

Similar Companies

kaerus bioscience limited

mavalon therapeutics limited

st&i partnerships limited

andrew reuter solutions limited

superx limited

company number

02575564

Type

Private limited with Share Capital

industry

72110 - Research and experimental development on biotechnology

incorporation date

January 1991

ultimate parent company

None

previous names

rashplay limited (February 1991)

address

2 gosforth park avenue, newcastle upon tyne, NE12 8EG

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to selective antibodies limited.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for SELECTIVE ANTIBODIES LIMITED. This can take several minutes, an email will notify you when this has completed.

selective antibodies limited Company Information

selective antibodies limited Estimated Valuation

selective antibodies limited Estimated Valuation

selective antibodies limited Estimated Valuation

Selective Antibodies Limited Overview

Selective Antibodies Limited Health Check

SELECTIVE ANTIBODIES LIMITED financials

selective antibodies limited Credit Report and Business Information

Selective Antibodies Limited Competitor Analysis

selective antibodies limited Ownership

selective antibodies limited directors

selective antibodies limited company details

selective antibodies limited Charges & Mortgages

selective antibodies limited Capital Raised & Share Issues BETA

selective antibodies limited Companies House Filings - See Documents